Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab-Reference-Cited by-同舟云学术

Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab

Published:2024-02-12 Issue:1 Volume:20 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Ziemssen Tjalf¹,Groth Marie²,Ettle Benjamin²,Bopp Tobias³

Affiliation:

1. Department of Neurology, Center of Clinical Neuroscience, Carl Gustav Carus University Clinic, University Hospital of Dresden, Technische Universität Dresden, Dresden, Germany

2. Medical Franchise Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany

3. Institute for Immunology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany

Funder

Novartis Pharma

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2316422

Reference14 articles.

1. Robert Koch-Institut. Stellungnahme der STIKO anlässlich der Zulassung von XBB.1.5-Varianten-adaptierten COVID-19-Impfstoffen für die Auffrischimpfung von Personen mit erhöhtem Risiko für einen schweren Krankheitsverlauf; 2023. https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Stellungnahme-COVID-19-Varianten-adaptierte-Impfstoffe.html. Robert Koch-Institut Stellungnahme der STIKO anlässlich der Zulassung von XBB.1.5-Varianten-adaptierten COVID-19-Impfstoffen für die Auffrischimpfung von Personen mit erhöhtem Risiko für einen schweren Krankheitsverlauf

2. World Health Organization. COVID-19 advice for the public: getting vaccinated; 2023. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice. World Health Organization COVID-19 advice for the public: getting vaccinated

3. Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis

4. Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab

5. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study